19 results about "Therapy resistant" patented technology

The invention belongs to the technical field of anti-tumor, and discloses application of HP and ICT combined anti-PD-1 inhibitor hydrogel in residual cancer recurrence after IRFA. The excellent drug delivery capacity of the hydrogel system is utilized, and the in-vivo local slow release effect of ICT and BMS202 can be remarkably amplified. Through synergistic treatment of the TAN and the MDSC, local and whole body adaptive immunoreactions can be efficiently activated, TAN is effectively reprogrammed to be in a tumor suppression type, infiltration of PMN-MDSC is reduced, and the conclusion is verified in a plurality of mouse tumor models in the chapter. Therefore, the HP (at) ICT / BMS provides a promising delivery strategy for improving the sensitivity of anti-PD-L1 treatment and efficiently preventing and treating latent residual cancer and metastasis after IRFA operation.

The present disclosure provides methods of identifying a disease or condition suitable for treatment with dupilumab. The present disclosure also provides methods of identifying a subject having a disease or condition suitable for treatment with dupilumab. The present disclosure also provides methods of carrying out a clinical trial for dupilumab treatment of a disease or condition.

The present application relates to the role of UCK1 in promoting the sensitization of colorectal cancer treatment. The present application discloses the key role of UCK1 in the treatment of colorectal cancer. Clinical samples show that the expression of UCK1 in tumor tissues is reduced, and its low expression is related to chemotherapy resistance and poor prognosis. Studies have shown that UCK1 enhances the efficacy of oxaliplatin (OXA) by regulating metabolic pathways, and promotes B cell activation, thereby recruiting CD8 + T cells, and strengthens anti-tumor immunity. UCK1 overexpression can significantly improve OXA sensitivity and produce a synergistic effect with anti-PD-1 therapy. The present application proposes a new strategy centered on activating UCK1, providing a theoretical basis and application prospect for improving the response of colorectal cancer chemotherapy and immunotherapy.

The invention discloses a biliary duct cancer PD-1 monoclonal antibody treatment prognosis prediction system based on blood magnesium level, and relates to the technical field of biliary duct cancer immunotherapy prognosis, the biliary duct cancer PD-1 monoclonal antibody treatment prognosis prediction system comprises four core modules, a blood magnesium detection module uses a full-automatic biochemical analyzer to detect serum magnesium, the serum magnesium is divided into a low magnesium group and a normal blood magnesium group, and synchronous quality control is performed; the clinical data acquisition module acquires multi-dimensional information, and two persons check and complement data; the prognosis analysis module integrates data, and evaluates prognosis through statistical test, survival analysis and subgroup verification; and the result output module generates an encrypted report, visually presents and synchronizes the encrypted report to the electronic medical record system. The serum magnesium is used as a prediction index, the cost is low, the serum magnesium is easy to obtain, the serum magnesium is adaptive to hospital equipment at all levels, the independent prediction value and subgroup consistency are confirmed through rigorous analysis, prognosis can be dynamically updated, individualized suggestions are generated, prediction accuracy and clinical practicability are improved, and biliary duct cancer immunotherapy precision is promoted.

All currently available treatment options for autoimmune encephalitis such as anti-NMDAR encephalitis and anti-LGI1 encephalitis carry substantial potential safety risks. Further, no approved therapies exist for anti-NMDAR encephalitis and anti-LGI1 encephalitis. The invention provides a means for a treatment for autoimmune encephalitis (AIE) such as NMDAR encephalitis and anti-LGI1 encephalitis, comprising an IL-6 inhibitor such as anti-IL-6 receptor antibody or antigen binding fragment thereof.

Provided herein are compositions and methods for treating spinal cord injury using nasal administration of anti-CD3 antibodies, e.g., foralumab.

Methods and apparatus disclosed treat pain and mobility impairments by applying controlled subatmospheric pressure to skin over muscle tissue or joints during volitional muscle contractions against adaptive therapist resistance. Domes with basal openings sealing against skin perimeters, are evacuated to 13-90% of atmospheric pressure. Some embodiments have 3-10 second contraction intervals repeated at least three times per subatmospheric treatment cycle, before pressure is ramped to ambient pressure over at least 2 seconds. Results are improved range of motion, muscle strength, and pain reduction. Apparatus embodiments include vacuum manifolds, sensors for pressure and tissue distension, and optional integrated electrodes for performing TENS / STIM.

Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.

The application discloses a kind of radiotherapy combined immunotherapy mouse liver injury model construction method and application, the construction method includes: using pentobarbital drug is anesthetized to mouse by intraperitoneal injection;Fix mouse exposure chest and abdomen;Depilating and marking liver position;Fixed front incisor and tail;In anesthetized state, the light of simulation machine is positioned at the liver area of mouse and illuminated, and the liver area is irradiated field, 100 μL of PD-1 antibody diluent is injected intraperitoneally once 1 day before whole liver irradiation, is injected once every 3 days, obtain radiotherapy combined immunotherapy mouse liver injury model, as animal model is used for screening the drug for preventing and treating liver injury caused by radiotherapy combined immunotherapy, including anti-CD20 antibody and its preparation, can prevent and relieve liver injury, and play an active role in liver disease treatment, further explore the important reference basis that anti-CD20 treatment is applied in liver disease treatment.

This invention discloses the application of ferritin heavy chain 1 (FTH1) inhibitors in the preparation of antitumor drugs. This invention collects pre-treatment FFPE tumor tissue from cancer patients receiving anti-PD-1 / L1 therapy. By integrating transcriptomic and proteomic data from baseline samples, FTH1 is screened as a key candidate molecule for immunotherapy resistance. Experiments demonstrate that FTH1 knockout significantly improves the sensitivity of cancer patients to anti-PD-1 / L1 immunotherapy and effectively inhibits tumor growth; conversely, FTH1 overexpression leads to resistance to anti-PD-1 / L1 immunotherapy. This invention can be applied to the development or preparation of antitumor drugs.

The invention relates to an application of an 18S rRNA m7G modified inhibitor in sensitization of PD1 in treatment of liver cancer. Through a large number of in-vivo and in-vitro experiments, it is clear that WBSCR22-mediated 18S rRNA m7G modification serves as a cancer promoting factor of liver cancer, and high expression and high modification level of the WBSCR22-mediated 18S rRNA m7G modification are closely related to tumor metastasis and poor prognosis. Through targeting WBSCR22 mediated 18S rRNA m7G modification, tumor migration can be inhibited, an immune microenvironment can be remodeled, generation of mtROS is promoted, and the expression level of inflammatory factors is improved, so that I-type interferon response caused by a cGAS-STING signal channel is activated, and the curative effect of anti-PD-1 treatment is remarkably improved. The invention has important practical significance for solving the problems of clinical curative effect difference and prognosis evaluation blank among individuals and better realizing accurate treatment. A new drug treatment target is provided for human to treat liver cancer, so that a new direction is provided for subsequent drug research and development, clinical treatment and the like, and extremely high social value and market application prospects are achieved.

The present invention relates to methods for predicting the probability of a treatment response of a human cancer patient to an immune checkpoint blocker treatment e.g. with anti PD-1, and to methods for predicting the probability of survival of a human cancer patient following an immune checkpoint blocker treatment, and to apparatuses and kits which can be used in these methods.

The disclosure is directed to treatment regimens for treating Multiple Sclerosis (MS). These methods utilize administration of ofatumumab, an anti-CD20 monoclonal antibody, to the patient during a loading dose regimen and a maintenance regimen.

The invention discloses a wAMD long-chain acyl carnitine detection method based on targeted metabonomics, and relates to the field of medical detection. Comprising the following steps: collecting aqueous humor samples of a wAMD patient and a cataract control group; performing qualitative and quantitative detection on the long-chain acyl carnitine LCACs in an aqueous humor sample by using a targeted metabonomics technology; the method comprises the following steps: screening differentially expressed LCCs molecules through data analysis, respectively collecting 10 samples of a wAMD patient and a cataract control group, collecting the samples of the wAMD group during anti-VEGF treatment, and collecting the samples of the cataract group during cataract surgery. The method can directly and efficiently detect the change of the LCADs in the aqueous humor of a wAMD patient, reveals the association between the LCADs and the wAMD pathology, and the identified key LCADs molecule can be used as a potential biomarker or a therapeutic target, and has important theoretical value and conversion prospect.

Offering extended interval administration of natalizumab. [Solution] Provided herein are methods for reducing the risk of developing progressive multifocal leukemia in patients receiving natalizumab therapy by switching to an extended interval dosing (EID) schedule, in some embodiments. In one embodiment, a method is provided for improving the safety of chronic natalizumab therapy, the method comprising determining whether a patient has at least one risk factor for PML, and, in the presence of at least one risk factor, administering natalizumab to the patient on an extended interval dosing (EID) schedule with intervals of at least 5 weeks.

The application belongs to the technical field of medical diagnosis, and discloses a marker for evaluating the curative effect of TACE combined with sindibimab and bevacizumab in treating hepatocellular carcinoma and a construction method and application of a FAAP prognosis scoring model. The application develops and verifies a FAAP prognosis scoring system, a new type of composite model integrating four indexes of fibrin degradation product / cholinesterase ratio x 1000 (FCR), aspartate aminotransferase (AST), alpha-fetoprotein (AFP) and portal vein tumor thrombus (PVTT), for predicting the survival of uHCC patients receiving TACE-sindibimab-bevacizumab triple therapy. The tool has instant clinical value, can optimize patient selection, guide adaptive treatment upgrade, and provide a standardized efficacy evaluation basis for exploring the clinical trials of TACE-immunotherapy-anti-angiogenesis combined schemes.

The application discloses an anti-Alzheimer's disease (AD) ultra-small nanodot with high BBB penetration and double targeting, and a preparation method and application thereof, and belongs to the field of nanomaterial preparation and biomedical application. The ultra-small nanodot is obtained by a self-assembly method according to a certain ratio of protein molecules, a five-membered peptide, ferrous ions (Fe 2+ ), and flavonoid drugs. The obtained ultra-small nanodot has the abilities of double targeting, high BBB penetration and multi-target point treatment of AD. Meanwhile, the preparation method is simple, raw materials are easy to obtain, the biological safety is good, the stability is high, the treatment level is various, and the ultra-small nanodot can be rapidly metabolized in a living body, and has the potential to be a safe and efficient multi-target point anti-AD therapeutic agent.

The application belongs to the technical field of biological medicine, and particularly relates to an anti-ACE2 antibody and application thereof. The antibody or antigen binding fragment thereof provided by the application comprises HCDR1, HCDR2 and HCDR3 contained in VH shown in SEQ ID NO:1, and LCDR1, LCDR2 and LCDR3 contained in VL shown in SEQ ID NO:2. The antibody provided by the application can block the combination of the spike protein of all current mutant strains and ACE2 in a broad spectrum without interfering with the enzyme activity of ACE2, and has excellent anti-SARS-CoV-2 treatment effect.